CN102065861B - 反式-4-((1r，3s)-6-氯-3-苯基茚满-1-基)-1，2，2-三甲基哌嗪用于改善认知的用途 - Google Patents

反式-4-((1r，3s)-6-氯-3-苯基茚满-1-基)-1，2，2-三甲基哌嗪用于改善认知的用途 Download PDF

Info

Publication number
CN102065861B
CN102065861B CN2009801162104A CN200980116210A CN102065861B CN 102065861 B CN102065861 B CN 102065861B CN 2009801162104 A CN2009801162104 A CN 2009801162104A CN 200980116210 A CN200980116210 A CN 200980116210A CN 102065861 B CN102065861 B CN 102065861B
Authority
CN
China
Prior art keywords
compound
cognitive
chloro
phenylindan
trimethylpiperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2009801162104A
Other languages
English (en)
Chinese (zh)
Other versions
CN102065861A (zh
Inventor
R·霍尔姆
C·考
B·威卢姆森
K·P·赫特尔
C·K·奥尔森
L·布鲁恩
K·K·索比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN102065861A publication Critical patent/CN102065861A/zh
Application granted granted Critical
Publication of CN102065861B publication Critical patent/CN102065861B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2009801162104A 2008-05-07 2009-05-07 反式-4-((1r，3s)-6-氯-3-苯基茚满-1-基)-1，2，2-三甲基哌嗪用于改善认知的用途 Expired - Fee Related CN102065861B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA200800647 2008-05-07
DKPA200800647 2008-05-07
DKPA200801392 2008-10-03
DKPA200801392 2008-10-03
DKPA200801519 2008-11-04
DKPA200801519 2008-11-04
PCT/DK2009/050107 WO2009135495A1 (en) 2008-05-07 2009-05-07 Method for treating cognitive deficits

Publications (2)

Publication Number Publication Date
CN102065861A CN102065861A (zh) 2011-05-18
CN102065861B true CN102065861B (zh) 2013-10-16

Family

ID=40870955

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801162104A Expired - Fee Related CN102065861B (zh) 2008-05-07 2009-05-07 反式-4-((1r，3s)-6-氯-3-苯基茚满-1-基)-1，2，2-三甲基哌嗪用于改善认知的用途

Country Status (15)

Country Link
US (2) US20090306092A1 (https=)
EP (1) EP2285377A1 (https=)
JP (1) JP2011519873A (https=)
KR (1) KR20110021754A (https=)
CN (1) CN102065861B (https=)
AU (1) AU2009243813B2 (https=)
BR (1) BRPI0912223A2 (https=)
CA (1) CA2722374A1 (https=)
CO (1) CO6311083A2 (https=)
EA (1) EA018927B1 (https=)
IL (1) IL209084A0 (https=)
MX (1) MX2010012037A (https=)
NZ (1) NZ589571A (https=)
WO (1) WO2009135495A1 (https=)
ZA (1) ZA201007912B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009298264A1 (en) * 2008-10-03 2010-04-08 H. Lundbeck A/S Oral formulation
JO3421B1 (ar) * 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
PL3135656T3 (pl) 2011-06-20 2019-07-31 H. Lundbeck A/S Deuterowane 1-piperazyno-3-fenyloindany do leczenia schizofrenii
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
EP3873885A1 (en) * 2018-10-29 2021-09-08 H. Lundbeck A/S Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
EP3891134A1 (en) 2018-12-03 2021-10-13 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022293A1 (en) * 1992-04-28 1993-11-11 H. Lundbeck A/S 1-piperazino-1,2-dihydroindene derivatives
WO2005016900A1 (en) * 2003-08-18 2005-02-24 H. Lundbeck A/S Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
CN101119983A (zh) * 2005-02-16 2008-02-06 H.隆德贝克有限公司 反式-1-((1r,3s)-6-氯-3-苯基茚满-1-基)-3,3-二甲基哌嗪的结晶碱
CN101119982A (zh) * 2005-02-16 2008-02-06 H.隆德贝克有限公司 反式-1-((1r,3s)-6-氯-s-苯基茚满-1-基)-3,3-二甲基哌嗪的酒石酸盐和苹果酸盐

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031216A (en) * 1974-08-12 1977-06-21 Knoll A.G. Chemische Fabriken 3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines
IE50867B1 (en) * 1980-02-29 1986-08-06 Kefalas As Indane derivatives
DE3139970A1 (de) * 1981-10-08 1983-04-28 Boehringer Mannheim Gmbh, 6800 Mannheim Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5026853A (en) * 1987-04-01 1991-06-25 Janssen Pharmaceutica N.V. 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
CA2091204C (en) * 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
CA2132411A1 (en) * 1994-09-19 1996-03-20 Michael Trani Enzymatic esterification of long-chain racemic acids and alcohols
US6410794B1 (en) * 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US6455736B1 (en) * 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US5807897A (en) * 1996-03-01 1998-09-15 Zeneca Limited Aminotetralin derivative and compositions and method of use thereof
DE69913332T2 (de) * 1998-05-01 2004-05-27 Pfizer Products Inc., Groton Verfahren zur herstellung von enantiomeren reinem oder optisch angereicherter sertraline-tetralon durch kontinuierliche chromatographie
DE19824470A1 (de) * 1998-05-30 1999-12-02 Boehringer Ingelheim Pharma Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
IN187170B (https=) * 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
IL162666A0 (en) * 2001-12-28 2005-11-20 Teva Pharma A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
WO2004039322A2 (en) * 2002-10-29 2004-05-13 Miicro, Inc. Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
US20080269248A1 (en) * 2005-02-16 2008-10-30 H. Lundbeck A/S Tartrate and Malate Salts of Trans-1-((1R,3S)-6-Chloro-3-Phenylindan-1-Yl)-3,3-Dimethylpiperazine
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
AU2009298264A1 (en) * 2008-10-03 2010-04-08 H. Lundbeck A/S Oral formulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022293A1 (en) * 1992-04-28 1993-11-11 H. Lundbeck A/S 1-piperazino-1,2-dihydroindene derivatives
WO2005016900A1 (en) * 2003-08-18 2005-02-24 H. Lundbeck A/S Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
CN101119983A (zh) * 2005-02-16 2008-02-06 H.隆德贝克有限公司 反式-1-((1r,3s)-6-氯-3-苯基茚满-1-基)-3,3-二甲基哌嗪的结晶碱
CN101119982A (zh) * 2005-02-16 2008-02-06 H.隆德贝克有限公司 反式-1-((1r,3s)-6-氯-s-苯基茚满-1-基)-3,3-二甲基哌嗪的酒石酸盐和苹果酸盐

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Klaus P. Bogeso.Enhanced D1 Affinity in a Series of Piperazine Ring Substituted l-Piperazino-3-Arylindanws ith Potential Atypical Antipsychotic Activity.《J. Med. Chem》.1995,第38卷(第22期),第4380-4392页. *

Also Published As

Publication number Publication date
IL209084A0 (en) 2011-01-31
WO2009135495A1 (en) 2009-11-12
CO6311083A2 (es) 2011-08-22
ZA201007912B (en) 2012-02-29
JP2011519873A (ja) 2011-07-14
HK1157674A1 (en) 2012-07-06
AU2009243813B2 (en) 2014-05-29
KR20110021754A (ko) 2011-03-04
EP2285377A1 (en) 2011-02-23
NZ589571A (en) 2012-07-27
CN102065861A (zh) 2011-05-18
MX2010012037A (es) 2010-11-30
AU2009243813A1 (en) 2009-11-12
CA2722374A1 (en) 2009-11-12
BRPI0912223A2 (pt) 2015-10-06
US20090306092A1 (en) 2009-12-10
EA201071273A1 (ru) 2011-06-30
US20110207744A1 (en) 2011-08-25
EA018927B1 (ru) 2013-11-29

Similar Documents

Publication Publication Date Title
CN102065861B (zh) 反式-4-((1r，3s)-6-氯-3-苯基茚满-1-基)-1，2，2-三甲基哌嗪用于改善认知的用途
Costall et al. Anxiolytic potential of 5‐HT3 receptor antagonists
Davies et al. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology
Bhana et al. Olanzapine: an updated review of its use in the management of schizophrenia
Nikiforuk et al. Amisulpride promotes cognitive flexibility in rats: the role of 5-HT7 receptors
JP2012504560A (ja) 経口製剤
Meneses et al. 5-HT1AReceptors Modulate the Consolidation of Learning in Normal and Cognitively Impaired Rats
JP6479766B2 (ja) 不安障害患者の治療のためのナルメフェン
KR20240005110A (ko) 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법
MX2007011436A (es) Ligando del receptor nicotinico neuronal 7 y composiciones antipsicoticas.
Synan et al. Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats
Kimani et al. Memory deficits associated with khat (Catha edulis) use in rodents
Higgins et al. Studies to examine potential tolerability differences between the 5-HT2C receptor selective agonists lorcaserin and CP-809101
KR20210151162A (ko) 자폐 범주성 장애를 치료하기 위한 카바모일 사이클로헥산 유도체
Erdinc et al. The efficacy of venlafaxine in the treatment of women with stress urinary incontinence
HK1157674B (en) Use of trans-4((1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine for improving cognition
Egyed et al. The Polypharmacology of Cariprazine and its Implications to Clinical Indications
Ballard et al. The drug-induced helplessness test: an animal assay for assessing behavioral despair in response to neuroleptic treatment
Waddington et al. The Neuroscience and Clinical Psychopharmacology of First‐and Second‐Generation Antipsychotic Drugs
Freudenreich et al. 7 Antipsychotic Drugs
Rashid et al. Phenothiazines and related antipsychotic drugs
Marek Developing serotonergic antidepressants acting on more than the serotonin transporter
GB2627332A (en) Compounds for use in the treatment of schizophrenia
Burroughs Assessment of Dopaminergic and Serotonergic Receptor Antagonists in Male Rats Trained to Discriminate 4-Methylmethcathinone (Mephedrone)
Collins Behavioral pharmacology of dopamine D2 and D3 receptor agonists and antagonists in rats

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1157674

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1157674

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131016

Termination date: 20160507